175 related articles for article (PubMed ID: 7622930)
41. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. II. Reactions.
Schreuder PA
Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):159-69. PubMed ID: 9728448
[TBL] [Abstract][Full Text] [Related]
42. Retrospective analysis of 194 leprosy cases in the Republic of Yemen.
Mekhlafi GA; al-Qubati Y
Indian J Lepr; 1996; 68(3):227-34. PubMed ID: 8889608
[TBL] [Abstract][Full Text] [Related]
43. Distinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric Study.
Costa MB; Cavalcanti Neto PF; Martelli CM; Stefani MM; Maceira JP; Gomes MK; Schettini AP; Rebello PF; Pignataro PE; Ueda ES; Narahashi K; Scollard DM
Int J Lepr Other Mycobact Dis; 2001 Sep; 69(3):177-86. PubMed ID: 11875761
[TBL] [Abstract][Full Text] [Related]
44. [Relapses after multibacillary leprosy treatment].
Rodríguez G; Pinto R; Laverde C; Sarmiento M; Riveros A; Valderrama J; Ordóñez N
Biomedica; 2004 Jun; 24(2):133-9. PubMed ID: 15495593
[TBL] [Abstract][Full Text] [Related]
45. Deformity incidence in leprosy patients treated with multidrug therapy.
Rao PS; Subramanian M; Subramanian G
Indian J Lepr; 1994; 66(4):449-54. PubMed ID: 7714354
[TBL] [Abstract][Full Text] [Related]
46. Clinical features of relapse after multidrug therapy for leprosy in China.
Shen J; Yan L; Sun P
Lepr Rev; 2015 Jun; 86(2):165-9. PubMed ID: 26502687
[TBL] [Abstract][Full Text] [Related]
47. Incidence of "chance" smear positivity among MB leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Indian J Lepr; 1995; 67(3):249-58. PubMed ID: 8576604
[TBL] [Abstract][Full Text] [Related]
48. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
49. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
51. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
52. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
Pandey A; Uddin MJ; Patel R
Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
[TBL] [Abstract][Full Text] [Related]
53. Indeterminate leprosy: histopathologic and histochemical predictive parameters involved in its possible change to paucibacillary or multibacillary leprosy.
Takahashi MD; Andrade HF; Wakamatsu A; Siqueira S; De Brito T
Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):12-9. PubMed ID: 2030308
[TBL] [Abstract][Full Text] [Related]
54. Unexplained delayed nerve impairment in leprosy after treatment.
Rosenberg NR; Faber WR; Vermeulen M
Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
[TBL] [Abstract][Full Text] [Related]
55. Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
Medeiros S; Catorze MG; Vieira MR
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):29-35. PubMed ID: 18713227
[TBL] [Abstract][Full Text] [Related]
56. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
57. Fixed-duration therapy (FDT) in multibacillary leprosy; efficacy and complications.
Vijayakumaran P; Jesudasan K; Manimozhi N
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):123-7. PubMed ID: 8690969
[TBL] [Abstract][Full Text] [Related]
58. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions.
Silva EA; Iyer A; Ura S; Lauris JR; Naafs B; Das PK; Vilani-Moreno F
Trop Med Int Health; 2007 Dec; 12(12):1450-8. PubMed ID: 18076551
[TBL] [Abstract][Full Text] [Related]
59. A simplified reverse transcriptase PCR for rapid detection of Mycobacterium leprae in skin specimens.
Phetsuksiri B; Rudeeaneksin J; Supapkul P; Wachapong S; Mahotarn K; Brennan PJ
FEMS Immunol Med Microbiol; 2006 Dec; 48(3):319-28. PubMed ID: 17052269
[TBL] [Abstract][Full Text] [Related]
60. Relapse in leprosy.
Kaimal S; Thappa DM
Indian J Dermatol Venereol Leprol; 2009; 75(2):126-35. PubMed ID: 19293498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
